US FDA questions data integrity in warning for Indian drugmaker

US FDA questions data integrity in warning for Indian drugmaker

Failing to ensure data integrity at a control laboratory in India has landed drugmaker USV with a US FDA warning letter.

The US Food and Drug Administration (FDA) inspected the site in Mumbai, India, last June and earlier this month sent USV – a maker of APIs, peptides, solid oral dose forms and biologics – a Warning Letter citing two specific violations of cGMP relating to data produced at the facility.

The firm failed to follow and document performance required laboratory control mechanisms, the FDA said in the letter, as well as failing to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records.

“The lack of reliability and accuracy of data generated by your firm is a serious CGMP deficiency that raises concern for all data generated by your firm,” the letter stated, citing as an example that sample weights used to calculate related compounds and impurities in drug applications were actually “backdated balance weight printouts produced after the analysis and generated for the notebooks.”

The agency also criticised the firm’s systems in the quality control (QC) laboratory with more than necessary personnel having access to high performance liquid chromatographs (HPLC) units and multiple users sharing computer logins.

Though USV had replied to the FDA, the agency noted the response “does not discuss how [it] will ensure that data audit trails will not be disrupted in the future and lacked a computer life cycle approach to, for example, assure routine verification of access controls in computer systems.”

GMP vigilance in India

Last summer, the FDA penalised fellow Indian drugmaker Posh Chemicals with a Warning Letter for failing to ensure data integrity and accused the firm of data falsification, whilst drugmaker Promed’s facility in Himachal Pradesh was also subject to a letter for a number of different GMP violations.

Furthermore, in the last few months Indian drugmakers Ranbaxy and Wockhardt have been subject to import alerts banning the supply of products into the US as the FDA push for a quality drive from oversea’s manufacturers.

Earlier this month, Commissioner Margaret Hamburg signed a statement of intent with the Indian authorities during a visit to the country. Since then, the FDA has begun recruiting to increase the number of inspectors in the country. 

Related News

Capitol hearing puts pressure on India to ramp up quality controls

Capitol hearing puts pressure on India to ramp up quality controls

Indian API maker slammed with US FDA Warning over data issues

Indian API maker slammed with US FDA Warning over data issues

Indian state regulator suspends manufacture of drug at Wockhardt plant

Indian state regulator suspends manufacture of drug at Wockhardt plant

Question? Sinequa will index data to answer AstraZeneca's queries. (Picture: Flickr/Roland O'Daniel)

AZ picks Sinequa to index millions of R&D docs

US FDA enforcement evolving in India will drive compliance costs

Indian firms must invest in compliance as USFDA ups enforcement, says S&P

Ipca halts API shipments to US following 483 at Indian plant

Ipca halts API shipments to US following 483 at Indian plant

Frogs, fungus and falsified data - Indian firm falls foul of US FDA

Frogs, fungus and falsified data - Indian firm falls foul of US FDA

FDA Warns Hospira Again, This Time in India

FDA Warns Hospira Again, This Time in India

US FDA is increasing its Indian drug inspector team

US FDA recruiting more inspectors in India as Hamburg pushes need for quality

US FDA’s Hamburg offers few details on trip to India

US FDA’s Hamburg offers few details on trip to India

Fake US FDA inspector targeting Indian drugmakers in latest scam

Fake US FDA inspector targeting Indian drugmakers in latest scam

Affordable isnt cheap Indian Gov tells FDA commish

Indian drugs affordable, not cheap minister tells US FDA

Wockhardt to Suffer Revenue Loss After FDA Import Alert

Ranbaxy was hit with another import alert from the FDA on Monday.

US FDA punishes Ranbaxy again with another import alert